SUPN Relative Valuation
SUPN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SUPN is overvalued; if below, it's undervalued.
Historical Valuation
Supernus Pharmaceuticals Inc (SUPN) is now in the Fair zone, suggesting that its current forward PE ratio of 17.27 is considered Fairly compared with the five-year average of 21.38. The fair price of Supernus Pharmaceuticals Inc (SUPN) is between 29.28 to 47.11 according to relative valuation methord.
Relative Value
Fair Zone
29.28-47.11
Current Price：32.34
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.82
P/B
Median3y
1.92
Median5y
1.91
7.78
FCF Yield
Median3y
7.31
Median5y
8.12
Competitors Valuation Multiple
The average P/S ratio for SUPN's competitors is 2.43, providing a benchmark for relative valuation. Supernus Pharmaceuticals Inc Corp (SUPN) exhibits a P/S ratio of 3.18, which is 30.59% above the industry average. Given its robust revenue growth of 4.30%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Supernus Pharmaceuticals Inc (SUPN) currently overvalued or undervalued?
What is Supernus Pharmaceuticals Inc (SUPN) fair value?
How does SUPN's valuation metrics compare to the industry average?
What is the current P/B ratio for Supernus Pharmaceuticals Inc (SUPN) as of Jul 19 2025?
What is the current FCF Yield for Supernus Pharmaceuticals Inc (SUPN) as of Jul 19 2025?
What is the current Forward P/E ratio for Supernus Pharmaceuticals Inc (SUPN) as of Jul 19 2025?